Business Insider covers the expanded provider access for HelioLiver beginning April 2026, detailing how healthcare providers with existing Quest accounts can order the blood-based liver cancer test through Quest's infrastructure of approximately 7,700 patient service centers and EHR integration. The article highlights quotes from CEO Dr. Bharat Tewarie calling it 'an important step in widening access to early cancer detection tools' and Quest's VP/GM of Oncology Asia Chang noting that 'liquid biopsy may play a meaningful role in aiding earlier cancer detection.'
Orange County Business Journal reports that Helio Genomics is now in full launch mode for HelioLiver through Quest Diagnostics, with the test commercially available nationwide through Quest's 7,700 patient service centers. CEO Dr. Bharat Tewarie reveals the company is developing two additional liver cancer tests — one to track treatment response and another to monitor for disease recurrence after liver transplant. Tewarie hints at additional partnership announcements in the coming months, stating 'partnerships help us scale in the most efficient manner.' The article also notes Helio submitted its FDA premarket approval application in 2024.
This syndicated GlobalData article examines how Helio Genomics' blood-based test detects tumor-associated epigenetic signals in cell-free DNA alongside protein biomarkers. It reports that five-year survival for liver cancer drops from 37% for localized disease to just 3% for distant disease, underscoring the urgent need for earlier detection. The article positions HelioLiver's Quest partnership alongside emerging Phase III immunotherapy trials like IMbrave050 and CARES-009, arguing that improved diagnostics and new treatments together could transform outcomes.
FinanceWire reports that Helio Genomics will make HelioLiver available through Quest Diagnostics starting April 2026. The article details how the test combines cell-free DNA methylation patterns, protein biomarkers, and patient demographics through a proprietary AI algorithm to detect hepatocellular carcinoma. Testing remains centralized at Helio's CLIA-certified laboratory in West Lafayette, Indiana, with sample collection supported by Quest's 7,700 patient service locations.
Originally published by Pharmaceutical Technology (a GlobalData brand), this analysis examines how Helio's blood-based multi-analyte approach detects tumor-associated epigenetic signals in circulating cell-free DNA alongside protein biomarkers — enabling earlier identification of cancer even where conventional imaging is inconclusive. The article reports SEER data showing five-year survival drops from 37% (localized) to 3% (distant), and positions the Quest partnership alongside Phase III perioperative immunotherapy trials (IMbrave050, CARES-009), arguing that improved diagnostics could expand the population eligible for curative interventions. Available via Yahoo! News syndication.
Dealroom.co reports that Helio Genomics has partnered with Quest Diagnostics to make HelioLiver widely available across the US starting April 2026. The article highlights that the test offers superior sensitivity to ultrasound for early-stage detection in high-risk individuals with cirrhosis or hepatitis B, noting that liver cancer incidence has tripled since 1980 while 80–90% of eligible adults skip recommended ultrasounds. Testing continues at Helio's West Lafayette laboratory.
Precision Medicine Online reports on Helio Genomics exploring new AI-driven diagnostic opportunities beyond liver cancer while preparing HelioLiver for broader US availability through Quest Diagnostics. The article suggests Helio is positioning its multi-analyte AI platform as a foundation for expanding into additional cancer types, signaling a broader pipeline strategy.
Simply Wall St. analyzes how Quest Diagnostics' partnerships with Helio Genomics and Guardant Health to distribute blood-based cancer screening tests could shape investor returns. The article notes that Quest's projected $11.9B revenue by 2028 depends on growing higher-value preventive and oncology testing, with the Helio partnership described as 'additive to that story.' The analysis estimates 12% upside to fair value at $218.50.
Scope Forward reports that starting April 2026, providers with a Quest account can order HelioLiver — a test designed for early detection of hepatocellular carcinoma — through Quest's network of approximately 7,700 patient service centers. The article notes the test will integrate into existing provider workflows and electronic health records systems.
LiverRight covers the Helio Genomics and Quest Diagnostics partnership, emphasizing that liver cancer incidence has tripled and mortality has doubled, yet 80–90% of at-risk patients don't get screened. The article highlights how HelioLiver combines cell-free DNA methylation analysis, protein biomarkers, and AI to detect cancer signals 'earlier than imaging alone' and notes that blood-based liver cancer screening is 'moving toward mainstream clinical adoption at scale.'
Becker's ASC Review reports that Quest Diagnostics will offer HelioLiver, Helio Genomics' blood-based test designed for early detection of hepatocellular carcinoma, through its nationwide provider network starting April 2026. The article, which was subsequently syndicated by NewsBreak to 13.9 million readers, highlights the test's availability through Quest's established ordering and EHR systems.
Brief Glance reports that HelioLiver achieved 76% sensitivity for early-stage liver cancer in the CLiMB clinical trial — substantially exceeding ultrasound's 47% sensitivity. The article notes HelioLiver identified 28.6% of tumors under 2cm while ultrasound detected none at that size. With liver cancer five-year survival at 70% when detected early, the Quest partnership across nearly 7,700 locations addresses the screening gap where 80–90% of eligible patients skip recommended biannual ultrasounds.
NewsBreak syndicated the Becker's ASC Review article announcing that Quest Diagnostics will offer HelioLiver through its nationwide network starting April 2026. The syndication amplified the story from Becker's clinical audience to NewsBreak's 13.9 million monthly visitors, demonstrating how top-tier news platforms rely on industry trade media to credential stories in cancer diagnostics.
SAHM Capital syndicates the Simply Wall St. analysis examining how Quest Diagnostics' partnerships with Helio Genomics and Guardant Health to distribute blood-based cancer screening tests will impact investor returns. The article frames these partnerships as additive to Quest's growth narrative around higher-margin advanced oncology testing, with projected 2028 revenue of $11.9 billion.
